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Contrasting Roles of Mitogen-Activated Protein Kinases in Cellular
Entry and Replication of Hepatitis C Virus: MKNK1 Facilitates Cell
Entry
Seungtaek Kim,a Hisashi Ishida,b* Daisuke Yamane,a MinKyung Yi,b David C. Swinney,c* Steven Foung,d Stanley M. Lemona
Division of Infectious Diseases, Department of Medicine, and the Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina, USAa; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USAb; Biochemical Pharmacology, Virology
DBA, Roche Palo Alto, Palo Alto, California, USAc; Department of Pathology, Stanford University School of Medicine, Stanford, California, USAd
The human kinome comprises over 800 individual kinases. These contribute in multiple ways to regulation of cellular metabo-
lism andmay have direct and indirect effects on virus replication. Kinases are tempting therapeutic targets for drug develop-
ment, but achieving sufficient specificity is often a challenge for chemical inhibitors. While using inhibitors to assess whether
c-Jun N-terminal (JNK) kinases regulate hepatitis C virus (HCV) replication, we encountered unexpected off-target effects that
led us to discover a role for a mitogen-activated protein kinase (MAPK)-related kinase, MAPK interacting serine/threonine ki-
nase 1 (MKNK1), in viral entry. Two JNK inhibitors, AS601245 and SP600125, as well as RNA interference (RNAi)-mediated
knockdown of JNK1 and JNK2, enhanced replication of HCV replicon RNAs as well as infectious genome-length RNA trans-
fected into Huh-7 cells. JNK knockdown also enhanced replication following infection with cell-free virus, suggesting that JNK
actively restricts HCV replication. Despite this, AS601245 and SP600125 both inhibited viral entry. Screening of a panel of inhib-
itors targeting kinases that may be modulated by off-target effects of AS601245 and SP600125 led us to identify MKNK1 as a host
factor involved in HCV entry. Chemical inhibition or siRNA knockdown of MKNK1 significantly impaired entry of genotype 1a
HCV and HCV-pseudotyped lentiviral particles (HCVpp) in Huh-7 cells but had only minimal impact on viral RNA replication
or cell proliferation and viability. We propose a model by whichMKNK1 acts to facilitate viral entry downstream of the epider-
mal growth factor receptor (EGFR) and extracellular signal-regulated kinase (ERK), both of which have been implicated in the
entry process.
Chronic infectionwith hepatitis C virus (HCV) is amajor causeof liver disease worldwide. Most infected persons fail to elim-
inate the virus following acute infection, placing them at risk for
chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma
(for a review, see reference 1). Classified within the genusHepaci-
virus of the family Flaviviridae, HCV is an enveloped virus with a
positive-sense, single-stranded RNA genome approximately 9.6
kb in length. A single open reading frame encodes a large precur-
sor polyprotein, which is processed into 10 proteins: core, E1, E2,
p7,NS2,NS3,NS4A,NS4B,NS5A, andNS5B (2). Core, E1, andE2
proteins are structural proteins that are present within the virion,
while the processed polyprotein segment extending from NS3 to
NS5B assembles into a replicase complex that directs synthesis of
the viral RNA (3). Because of its importance as a humanpathogen,
both HCV replication mechanisms and host responses that re-
strict HCV infection have been intensively studied. Such knowl-
edge has led to the development of new direct-acting antiviral
drugs that offer increasing opportunities for eliminating HCV in-
fections and either arresting or reversing the progression of liver
disease. Despite this, major gaps remain in our understanding of
the biology of HCV.
One unanswered question that has relevance for both vaccine
development and antiviral therapy is why host responses are able
to successfully eliminate HCV in a minority of infected individu-
als while infections become persistent in others. Innate host re-
sponses to HCV seem likely to play a primary role in the early
elimination of virus, as this correlates strongly with polymor-
phisms in the interleukin-28B (IL-28B) (gamma 3 interferon
[IFN-3]) gene (4). IFN-mediated Janus kinase signal transducer
and activator of transcription (JAK-STAT) signaling results in
strong anti-HCV activity and likely contributes to viral control by
stimulating the expression of numerous antiviral proteins, includ-
ing protein kinase R, 2=,5=-oligoadenylate synthetase, MxA, vi-
perin, interferon-stimulated gene 21, and others (5). Other cellu-
lar signaling pathways also have been shown to suppress HCV
replication, including those triggered by protein kinase C (6),
phosphoinositide-3 (PI3) kinase (7, 8), SMAD (9), extracellular
signal-regulated kinase (ERK) (7, 10, 11), and p38 kinase (12).
Although there is limited understanding of how intracellular
signaling restricts HCV replication, mitogen-activated protein ki-
nases (MAPKs) appear to play an essential role. These are versatile
serine/threonine kinases involved in signal transduction that
modulate gene transcription in response to changes in extracellu-
lar stimuli (13). They control numerous fundamental cellular
processes, including proliferation, differentiation, migration, and
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apoptosis. Three MAPK cascades have been defined, including
those centered on ERK, c-Jun N-terminal kinase (JNK), and p38.
ERK and p38 signaling are both antagonistic to HCV replication
(7), while the impact of JNK activation has not been studied. JNKs
(comprised of JNK1, JNK2, and JNK3) are activated by a variety of
cytotoxic stresses, such as UV irradiation, heat/osmotic shock,
and oxidative stress, and proinflammatory cytokines, including
tumor necrosis factor- (TNF-), interleukin-1 (IL-1), and trans-
forming growth factor- (TGF-) (14). Moreover, innate im-
mune responses induced by Toll-like receptor (TLR) recognition
of invading pathogens activate JNK signaling (15), suggesting that
JNKs act as intermediates in antiviral signaling. Activated JNKs
are phosphorylated and, in turn, phosphorylate a variety of sub-
strates, including transcription factors, Bcl2 family members, and
cytoskeleton molecules.
While such cell signaling may limit infection, signaling via
other pathways appears to be essential for entry of HCV into the
host cell. Several host proteins are involved in this process, includ-
ing the tetraspanin CD81 (16, 17), scavenger receptor class B type
I (SR-BI) (18, 19), and the tight junction proteins claudin-1
(CLDN1) (20) and occludin (OCLN) (21), as well as the recently
identified Niemann-Pick C1-like 1 (NPC1L1) protein (22). Viral
entry is initiated by the binding of virus to glycosaminoglycans
(23, 24) and/or the low-density lipoprotein (LDL) receptor (25)
on the cell surface, followed by subsequent steps involving scav-
enger receptor B1 (SR-BI), CD81, CLDN1, andOCLN, ultimately
leading to clathrin-mediated endocytosis of the virus (26, 27; for a
review, see reference 28).Whilemechanistic details of this process
remain to be elucidated, several lines of evidence suggest that host
kinases play critical roles. Inhibition of protein kinase A (PKA)
limits HCV entry and alters the pattern of CLDN1 expression
(29), while a comprehensive RNA interference (RNAi) screen
identified epidermal growth factor receptor (EGFR) and ephrin
receptor A2 (EphA2) as additional host factors (30). EGFR activa-
tion enhanced HCV entry by regulating CD81 interactions with
CLDN1 and membrane fusion, although the downstream signal-
ing pathways were not elucidated. ERK activation has also been
linked to CD81 engagement (31).
Here, we describe experiments aimed at determining whether
JNK signaling regulates HCV infection. We found that chemical
inhibitors of JNK (AS601245 and SP600125) or siRNA knock-
down of JNK expression enhanced replication of viral RNA, indi-
cating a negative regulatory role for JNK kinases. Nonetheless, an
off-target effect of these JNK inhibitors blocked infection with
cell-free virus, leading to recognition of the involvement of a
MAPK-related kinase, MAPK interacting serine/threonine kinase
1 (MKNK1), in viral entry.
MATERIALS AND METHODS
Cells and viruses. The human hepatocellular carcinoma cell lines Huh-7
and Huh-7.5 were cultured in high-glucose Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum and 1 penicillin-
streptomycin at 37°C in a 5% CO2 environment. NNeo/3-5B/RG (RG)
and NNeo/C-5B/2-3 (2, 3), Huh-7 clonal cell lines that harbor HCV-N
(genotype 1b) subgenomic replicon RNA and genome-length replicon
RNA, respectively (32), were maintained in complete DMEM with 250
g/ml of G418. HJ3-5 andH77S.2 viruses have been described previously
(33, 34). Plasmids encoding infectious chimeric genotype 1a (structural)
and 2a (nonstructural proteins)HCV genomes,HJ3-5,H-NS2/NS3-J (34,
35), and HJ3-5/GLuc2A (that expresses Gaussia princeps luciferase
[GLuc]) (36) have been described previously. Retroviral particles pseu-
dotyped with the H77c envelope (HCVpp) and vesicular stomatitis enve-
lope protein (VSVpp) were prepared as described previously (37).
Reagents and antibodies. Antibodies to JNK, phospho-JNK,
MKNK1, NPC1L1, and Myc-Tag were purchased from Cell Signaling
Technology. Antibodies to -actin (A-5441) and FLAG (F-3165) were
from Sigma-Aldrich. Antibodies to claudin-1 (clone 2H10D10) and oc-
cludin (OC-3F10) were from Invitrogen. Antibodies to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (AM4300) and SR-BI (NB400-104)
were purchased from Ambion and Novus Biologicals, respectively. A
mouse monoclonal antibody to the HCV core protein (C7-50) and rabbit
polyclonal antibody to CD81 (PA5-13582) were obtained from Thermo
Scientific. Rabbit antibody to HCV NS5A was the generous gift of Craig
Cameron. JNK inhibitors SP600125 and AS601245 were purchased from
Calbiochem.
Plasmids and DNA transfection. pRLHL, a dicistronic, dual lucifer-
ase reporter plasmid containing the HCV internal ribosome entry site
(IRES) within its intercistronic space, has been described (38). pCMV-
GLuc was purchased fromNew England BioLabs, Inc. An expression vec-
tor for JNK2 (pcDNA-FLAG-JNK2) was constructed by amplifying spe-
cific cDNA using conventional reverse transcription-PCR (RT-PCR)
methods and cloning the amplified sequences into the HindIII-EcoRI site
of pcDNA6/V5-HisB with FLAG sequence at the N terminus of the gene.
pcDNA-Myc-MKK73E, an expression vector for constitutively active
MKK7, was constructed by inserting the cDNA of MKK7 into the KpnI-
XbaI site of pcDNA6/V5-HisB with a myc sequence at the N terminus of
the gene, followed by site-specific mutagenesis of S271E, T275E, and
S277E using a QuikChange site-directed mutagenesis kit (Stratagene).
Transfection of plasmid DNAs was accomplished with Fugene 6 (Roche)
according to the manufacturer’s recommended procedures.
RNA transcription and transfection. In vitro transcription of HCV
RNA and transfection were performed as previously described (39).
Kinase inhibitor screen.NaïveHuh-7.5 cells (2 105 cells/well) were
plated in 6-well culture dishes, and 24 h later they were treated with var-
ious chemical inhibitors of selected kinases (see Results) at 10 M for 1 h
prior to inoculation with virus (HJ3-5) at a multiplicity of infection
(MOI) of 1 in the presence of the inhibitor. Inhibitors were diluted in
dimethyl sulfoxide (DMSO) (final concentration,0.1%). The cells were
then washed twice with PBS and refed with fresh culture mediumwith no
inhibitor. Cells were harvested 3 days later for immunoblotting with an-
tibodies toHCVcore protein.Dose-ranging experiments to determine the
effective inhibitory concentrations (ICs) of kinase inhibitors were carried
out similarly.
Inhibition of FFU formation and HCVpp entry. Huh-7.5 cells (1
105 cells/well) were plated in an 8-well chamber slide (Lab-Tek). Inhibi-
tors were added to the medium 1 h prior to inoculation with HJ3-5 virus,
H77cHCVpp, or VSVpp. VSVppwas diluted 1:20 prior to inoculation, so
that it produced luciferase activity approximating that obtained with
HCVpp in untreated cells. Virus was allowed to adsorb for 6 h in the
presence of the inhibitor, followingwhich the cells werewashed twicewith
PBS and refed with fresh medium containing no inhibitor. The cells were
processed 2 days later for detection of foci of infected cells by immuno-
staining with antibody to core protein, as described previously (34) (HJ3-
5-infected cells), or lysed for luciferase assay (HCVpp and VSVpp). In
related experiments, cells were treated with the inhibitor for 6 h prior to
virus inoculation or after virus adsorption and then similarly processed.
Luciferase assay. Cell lysates were prepared with Passive Lysis buffer
(Promega), and luciferase activity was measured by Luciferase Assay sys-
tems (Promega) by following the manufacturer’s protocol. For the mea-
surement of GLuc activity, we followed the method described by Shi-
makami et al. (33)
RNAi. Short interfering RNAs (siRNAs) for JNK1 (J-003514-17),
JNK2 (J-003505-18), MKNK1 (L-004879-00-005), and MKNK2 (L-
004908-00-0005) were purchased from Thermo Scientific. Transfection
of siRNAs was accomplished by either Oligofectamine (Invitrogen) or
TransIT-TKO transfection reagent (Mirus) by following the manufactur-
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er’s recommended procedures. For the infection experiment, 2 days after
transfection, the cells were trypsinized and seeded in a 48-well culture dish
(1 105 cells/well). One day after seeding, the cells were incubated with
viruses (HJ3-5 or HCVpp) for 6 h. The cells were washed with phosphate-
buffered saline (PBS) and refedwith freshmedium. The cells were fixed 48
h later for counting the number of infectious foci or lysed for luciferase
assay.
Cell proliferation assay. Cell proliferation was assessed by WST-1
(2-[2-methoxy-4-nitrophenyl]-3-[4-nitrophenyl]-5-[2,4-disulpho-
phenyl]-2H-tetrazolium, monosodium salt) assay according to the man-
ufacturer’s suggested protocol (Millipore).
Northern blotting. Total cellular RNA was extracted using TRIzol
reagent (Invitrogen). Six g of total RNA was electrophoresed and trans-
ferred to a nylon membrane (Hybond-N; GE Healthcare). The mem-
brane was probed with in vitro-transcribed negative-strand HCV RNA
labeled with digoxigenin (DIG), using reagents provided with the DIG
Northern Starter kit (Roche Applied Science) and by following the
manufacturer’s recommended procedures. After extensive washing
and blocking, the membrane was hybridized with anti-digoxigenin-AP,
incubated with disodium 3-(4-methoxyspiro {1,2-dioxetane-3,2=-(5=-
chloro)tricyclo [3.3.1.13,7]decan}-4-yl)phenyl phosphate (CSPD), and
exposed to a BioMax MR X-ray film (Eastman Kodak).
Immunoblotting. Standard immunoblotting procedures were fol-
lowed (40). Proteins transferred to a polyvinylidene difluoride (PVDF)
membrane were probed with specific primary antibodies (as described
above), followed by further incubation with a secondary antibody conju-
gatedwith horseradish peroxidase (GEHealthcare) or IRDye 800CWgoat
anti-mouse IgG or IRDye 680 goat anti-rabbit IgG (LI-COR Biosciences).
Proteins were visualized by ECLWestern blotting detection reagents (GE
Healthcare) or an Odyssey infrared imaging system (LI-COR Biosci-
ences).
qRT-PCR. For quantitative RT-PCR (qRT-PCR), total cellular RNA
was prepared with an RNeasy Minikit (Qiagen). mRNAs for MKNK1,
MKNK2, andGAPDHwere quantified by a CFX96 real-time system (Bio-
Rad) using an iScript One-Step RT-PCR kit with SYBR green (Bio-Rad).
Primer sequences were 5=CCAGGCAGGCCGTGGTGAAG 3= and 5= AG
CGGTGAGAGCAGGCTGGA 3= for MKNK1 mRNA and 5= AGGAAGA
TGTGCTGGGGGAG 3= and 5= CCTGGCACTGGTACAGCATC 3= for
MKNK2 mRNA.
RESULTS
JNK activation restricts replication of HCV replicon RNA. To
determine whether JNK signaling regulates replication of HCV
RNA, we treated a cell line containing a subgenomic HCV RNA
replicon, RG,with two chemical inhibitors of JNK,AS601245 (1 to
10 M) and SP600125 (2.5 to 20 M). Both inhibitors increased
NS5A abundance in a dose-dependent fashion (Fig. 1A). Both
JNK inhibitors also increased the abundance of the HCV replicon
RNA, although SP600125 had a greater effect on this than
AS601245 (Fig. 1B). Significantly, cellular proliferation was re-
duced at the higher concentrations of these compounds, as evi-
denced inWST-1 assays (Fig. 1C). Thus, the increase in viral RNA
and viral protein abundance could not be attributed to a reversal
of JNK suppression of cell growth (41). Moreover, since the re-
duced cellular proliferation observed at these concentrations
could be expected to have a negative effect on HCV replication
(42), the increase inHCVRNA abundance that we observed when
RG cells were treated with these high concentrations of the inhib-
itors may underrepresent the degree to which JNK-mediated con-
trol of replication is derepressed. Similar effects were observed
with a genome-length replicon cell line (data not shown).
To confirm the results obtainedwith these chemical inhibitors,
we assessed the effect of siRNA-mediated knockdown of JNK on
the replicon. There are three JNK isoforms (JNK1, JNK2, and
JNK3), each of which is expressed as a short (46 kDa) and long
species (54 kDa) (43). RT-PCR assays detected only JNK1 and
JNK2 transcripts in RG cells (data not shown). This was as ex-
pected, since RG cells are derived fromHuh-7 hepatoma cells, and
JNK3 expression is restricted to heart, brain, testis, and pancreatic
 cells (43). Thus, we used only JNK1- and JNK2-specific siRNA
pools to knock down JNK expression. Immunoblots using anti-
JNK antibody revealed one major 54-kDa band and three bands
migrating with a mass close to 46 kDa in these cells (Fig. 1D). The
most rapidly migrating 46-kDa band was reduced by JNK1-spe-
cific siRNA, while the 54-kDa and middle 46-kDa bands were
decreased with JNK2-specific siRNA. The most slowly migrating
46-kDa band was unchanged with either siRNA and is likely to be
nonspecific. Antibodies to phospho-JNK (Thr183/Tyr185) re-
acted with both the 54-kDa and most rapidly migrating 46-kDa
species (corresponding to JNK2 and JNK1, respectively). Thus,
both JNK1 and JNK2 are activated and likely to contribute to JNK
signaling in these Huh-7-derived cells, although the underlying
mechanism responsible for JNK activation is uncertain. As we
anticipated from the studies with chemical inhibitors, knockdown
of either JNK1 or JNK2 resulted in an increase in NS5A abun-
dance, while combined knockdown of both JNK1 and JNK2 had
an additive effect on NS5A abundance (Fig. 1D) and resulted in a
clear increase in replicon RNA abundance (Fig. 1E). We conclude
from these results that JNK activation restricts the replication of
HCV replicon RNAs.
JNK suppresses replication of infectious virus. To confirm
that JNK has similar effects on replication of infectious virus, we
transfected Huh-7 cells with JNK1- and JNK2-specific siRNAs
prior to inoculation with HJ3-5, a genotype 1a/2a chimeric virus
(35). Cells were infected at an MOI of 2 and then monitored for
viral protein abundance and yields of infectious virus released into
the media. As shown in Fig. 2A, knockdown of JNK1 and JNK2
expression led to a significant increase in core protein expression
and a doubling of the infectious virus yield at both 48 and 72 h
postinfection. Conversely, JNK activation suppressed HCV repli-
cation. To activate JNK, we cotransfected expression vectors for
JNK2 and MKK73E, a constitutively active form of mitogen-acti-
vated protein kinase kinase 7 (MAP2K7, orMKK7) that acts as an
upstream activator of JNK (44). While independent expression of
either JNK2 or MKK73E had little effect on the abundance of
phosphorylated JNK, their coexpression resulted in substantial
JNK activation (Fig. 2B, left). This was reflected in reduced core
protein expression (Fig. 2B, center) and infectious virus yields
(Fig. 2B, right). These results indicate that JNK activation not only
suppresses amplification of replicon RNAs but also restricts rep-
lication of infectious virus.
Off-target effects of AS601245 and SP600125 inhibit HCV
entry. Given the results described above, we anticipated that the
chemical inhibitors of JNK would also enhance replication of in-
fectious virus. To confirm this, we pretreated Huh-7 cells with 2.5
M AS601245 or 10 M SP600125 for 1 h prior to inoculation
with HJ3-5 virus at a multiplicity of 2. After 6 h of incubation at
37°C for virus adsorption, the cells were washed with PBS and
refed with medium containing the inhibitors. Surprisingly, both
core protein expression levels and infectious virus yields were
sharply reduced by both inhibitors compared to levels for non-
treated cells (Fig. 2C). Subsequent studies demonstrated that
AS601245 possessed a 50% effective antiviral concentration
Kim et al.
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(EC50) of 0.92M, and SP600125 had an EC50 of 3.8M (Fig. 3A
andB). These concentrations arewithin the range commonly used
for JNK inhibition and do not negatively impact proliferation of
Huh-7 cells in WST-1 assays (Fig. 1C).
Since both AS601245 and SP600125 inhibit replication of in-
fectious virus (Fig. 2C and 3) yet stimulate replication of replicon
RNAs (Fig. 1A and B), we suspected that they block a step in viral
entry, or possibly assembly and release. This would be an off-
target effect of these kinase inhibitors, since specific RNAi-medi-
ated knockdown of JNK enhances replication of infectious virus
(Fig. 2A). To better characterize this off-target effect, wemeasured
the number of infectious foci formed in cells inoculated at a low
multiplicity of infection with genotype 1a H77S.2 virus (33, 45) in
the presence or absence of AS601245 or SP600125. Both inhibitors
FIG 1 JNK inhibition enhances HCV RNA abundance in replicon cells. (A) Effect of JNK inhibitors AS601245 and SP600125 on HCV replicon abundance. RG
cells were treated with AS601245 (1 to 10 M) or SP600125 (2.5 to 20 M) for 24 h prior to harvesting and immunoblot assay for NS5A expression. (Left)
Immunoblots of NS5A and -actin, a loading control. (Right) Mean relative NS5A abundance  standard deviations (SD) at 2.5 M AS601245 or 10 M
SP600125 in 3 independent experiments. Protein abundance was quantified by densitometry and calculated as the amount relative to that in lysates of untreated
cells (considered 1). (B) Northern blot analysis showing abundance of HCV replicon RNA in RG cells treated with 2.5 MAS601245 (AS) or 10 M SP600125
(SP) for 2 or 3 days. 18S and 28S ribosomal RNAs are shown as a loading control. At the bottom are immunoblots of NS5A and-actin in cell lysates. (C) Impact
of AS601245 (0 to 10 M) or SP600125 (0 to 20 M) on cellular proliferation. WST-1 assay was carried out on cells incubated for 1, 2, or 3 days in media
containing inhibitors.Mean values at an optical density of 540 nm (OD450) were calculated from triplicate experiments. (D)RNAi knockdownof JNK1 and JNK2
enhances replicon RNA abundance. RG cells were transfected with JNK1-specific, JNK2-specific, a combination of JNK1- and JNK2-specific siRNAs (JNK12),
or negative-control siRNAs 3 days prior to being harvested for immunoblotting. (Upper) Immunoblots of NS5A, total JNK, phosphorylated JNK, and -actin.
(Lower) Relative NS5A abundance (means SD) in 3 independent transfection experiments. Protein bands were quantified as described for panel A; an asterisk
signifies a nonspecific protein band. (E) Northern blot showing replicon RNA abundance in RG cells transfected 3 days previously with JNK1- and JNK2-specific
or control siRNAs.
MKNK1-Dependent HCV Infection
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resulted in an approximately 80% reduction in the number of
infectious foci (Fig. 3C). This was not due to inhibition of H77S
RNA replication, as there was only a minimal (SP600125) or no
(AS101245) effect on yields of infectious virus released from cells
that were treated with the inhibitors for 48 h after transfection
with H77S.2 RNA (Fig. 3D). Similarly, there was little effect on
core protein expression, a measure of viral replication, in cells
transfected with a replication-competent HCV RNA (H-NS2/
NS3-J) that is incapable of directing assembly of infectious virus
particles (35) (Fig. 3E). These results point strongly toward an
off-target effect of these JNK inhibitors that hits a key step inHCV
entry.
Identification of MKNK as a host factor in HCV entry. The
specificity of chemical inhibitors of kinases is notoriously difficult
to control, as exemplified by these results. Several kinases have
been implicated previously in HCV entry, as described above, and
the JNK inhibitors are likely to have nonspecific activity against an
additional, unidentified kinase involved in this process. To iden-
tify this kinase, we screened a panel of chemical inhibitors target-
ing four candidate kinases, each of which was considered to be
subject to off-target inhibition by the JNK inhibitors studied
above (unpublished data from Roche): RO5096129, targeting cy-
clin G-associated kinase (GAK); RO4475417, targeting MKNK;
RO4567182, targeting CDC-like kinase 2 (CLK2); and
RO5071631, targeting TTK protein kinase (TTK). We also tested
RO5108581, a novel inhibitor with high specificity for JNK. Each
of these compounds inhibits its target kinase bymore than 90% at
10M(data not shown), the concentration used for initial screen-
ing experiments. Cells were treated with compound for 1 h prior
to inoculation with HJ3-5 virus (MOI of 1), following which the
virus was allowed to adsorb to cells in the presence of the com-
pound for 6 h. This was followed by extensive washing of the cells
and refeeding with normal media (no compound). Under these
conditions, the MKNK inhibitor (RO4475417) caused a signifi-
cant decrease in HCV core protein expression, as measured by
immunoblots of cell lysates prepared 72 h postinfection (Fig. 4A,
FIG 2 Contrasting effects of genetic manipulation versus chemical inhibition of JNK on infection with cell-free HCV. (A) JNK knockdown enhances the
replication of HCV in Huh-7 cells. (Left) Cells were transfected with negative-control or JNK1- and JNK2-specific siRNAs prior to inoculation with HJ3-5 virus
at an MOI of 2. Cell lysates prepared 1, 2, and 3 days postinfection were assayed for core, JNK, and -actin proteins. Immunoblottings for core protein were
carried out using 1 or 5 g of total protein resolved in each lane. (Right) HJ3-5 virus titers in supernatant media collected 2 and 3 days postinfection. Error bars
indicate SD in replicate experiments. (B) JNKactivation suppressesHCV replication inHuh-7 cells. (Left) Cells were transfectedwith expression vectors for JNK2
(pCMV-FLAG-JNK2) and constitutively active MKK7 (pCMV-Myc-MKK73E). After incubation for 2 days, cells were harvested, followed by immunoblot
analyses for total and phosphorylated JNK, ectopically expressed JNK2 (using anti-FLAG antibody), ectopically expressedMKK73E (using anti-Myc antibody),
and -actin. (Middle) Cells were cotransfected with pCMV-FLAG-JNK2 and pCMV-Myc-MKK73E or were transfected only with an equal amount of empty
vector (pcDNA6/V5-HisB) prior to inoculation with HJ3-5 virus. Cells were harvested 1, 2, and 3 days later, and lysates were assayed for core, FLAG (tagged to
JNK2), Myc (tagged to MKK73E), and -actin proteins. (Right) HJ3-5 virus titers in supernatant fluids were determined 2 and 3 days postinfection. (C) JNK
inhibitors AS601245 and SP600125 suppress infection by cell-free virus. (Left) Cells were pretreatedwith 2.5MAS601245, 10MSP600125, orDMSO1hprior
to inoculation with HJ3-5 virus at anMOI of 2. Cells were then cultured in media containing the inhibitors for 1, 2, and 3 days prior to preparation of lysates for
assay of core and -actin proteins. (Right) HJ3-5 virus titers in supernatant fluids 2 and 3 days postinfection.
Kim et al.
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upper). Importantly, the compound had a much more limited
effect on core protein expressionwhen it was used to treat the cells
for 6 h prior to infection andwashed out prior to virus inoculation
(Fig. 4A, lower), while the other inhibitors had no effect under
either set of conditions. These results are consistent with the
MKNK inhibitor blocking an early step in the virus life cycle.
To more fully characterize this effect, we treated cells with a
range of concentrations of RO4475417 for 1 h prior to and during
a 6-h period of virus adsorption (Fig. 4B).We then compared core
protein expression (quantitative immunoblotting) at 72 h to ef-
fects on cellularmetabolism (WST-1 assay) at 48 h. The reduction
in core protein expression was dose related and virtually complete
at 20 M. At this concentration, RO4475417 had only a modest
negative effect in the WST-1 assay, consistent with a role for
MKNK in cell death and survival (46). We also infected cells at a
low multiplicity in the presence or absence of RO4475417 and
counted the number of foci of infected cells formed at 48 h (Fig. 4C).
FIG 3 Suppression ofHCV infection ofHuh-7 cells by increasing concentrations
ofAS601245 or SP600125. (A)Cells were pretreatedwithAS601245 (0 to 2.5M)
or SP600125 (0 to 10M) for 1 h prior to inoculation with HJ3-5 virus and then
weremaintained inmedia containing the inhibitors. Lysates prepared 3days post-
inoculationwereassayed for coreand-actinproteinabundanceby immunoblot-
ting. (B) Titer of infectious virus released from HJ3-5-infected cells treated as
described for panel A. Infectious virus yields weremeasured in supernatant fluids
collected on day 3 postinoculation using an FFU assay (45). (C) Inhibition of
infectious focus formation by 2.5 M AS601245 or 10 M SP600125 versus
DMSO control (None). (Top) Huh-7 cells were inoculated with genotype 1a
H77S.2 virus (33) in the presence of compounds at time point 0. Medium was
replaced at 24-h intervals, and the cells were fixed for detection of replication foci
by indirect immunofluorescence for core protein at 96 h. The shaded bar repre-
sents the period of exposure to compounds. (Bottom) FFU enumerated at 96 h.
(D) Lack of suppression ofHCVRNAreplication and infectious virus production
by equivalent concentrations of the JNK inhibitors tested inpanelC. (Top)Huh-7
cells were electroporatedwith in vitro-transcribedH77S.2 RNA and then fed 4.5 h
later, when they were adherent to the vessel surface, with medium containing 2.5
M AS601245, 10 M SP600125, or DMSO only. Cells were refed at 24 h with
media containing the compounds (shaded segment of timeline) and then at 48 h
withmedia containingno inhibitors. Supernatantfluidsharvested fromthecells at
72 h were assayed for the presence of infectious virus in an FFU assay. (Bottom)
Infectious virus yields fromRNA-transfected cells. Data shown in panels C andD
representmeans SD from triplicate or duplicate cultures. (E)Cellswere electro-
porated with H-NS2/NS3-J RNA (35) and then treated with AS601245 (2.5M)
orSP600125(10M).Cellswereharvestedat24-h intervals tomonitor expression
of HCV core and -actin (loading control) proteins by immunoblotting.
FIG 4 Screening of kinases that may be targeted nonspecifically by JNK in-
hibitors. (A) Huh-7.5 cells were treated with selected kinase inhibitors (10M
concentration) for either (top) 1 h prior to infection byHJ3-5 virus and during
a 6-h period of viral adsorption thereafter, or (bottom) 6 h prior to virus
inoculation. Kinases included RO4475417, which inhibits MKNK;
RO5096129, an inhibitor ofGAK; RO5071631, a TTKprotein kinase inhibitor;
RO5108581, a JNK inhibitor; and RO4567182, a CLK2 inhibitor. Following
virus adsorption, cells were cultured in the absence of inhibitors. Cell lysates
were prepared on day 3 for immunoblotting for HCV core protein. (B) Com-
parison of HCV inhibitory and cytotoxic effects of increasing concentrations
of RO4475417 (MKNK inhibitor). Huh-7.5 cells were pretreated with the in-
hibitor for 1 h prior to a 6-h HJ3-5 virus adsorption period, then they were
washed prior to refeeding withmedium containing no inhibitors. HCV inhib-
itory activity was assessed by quantitative immunoblotting for core protein at
72 h, while cytotoxicity was determined by WST-1 cellular proliferation assay
48 h after inhibitor treatment (the midpoint in the virus growth period).
Means standard errors (SE)were calculated from triplicate experiments. (C)
RO4475417 inhibition of infectious focus formation. Huh-7.5 cells were
treatedwith increasing concentrations of compound for either 1 h prior to and
then during a 6-h period of HJ3-5 virus adsorption (	1 to 6 h) or a 6-h period
following virus adsorption (6 to 12 h), as shown schematically. Cells were then
washed and refed with media containing no compound. Cells were fixed at 48
h, and FFUwere enumerated as described in the legend to Fig. 3C.Means SE
were calculated from two independent experiments.
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Increasing concentrations of theMKNK inhibitor, added 1 h prior
to infection and continued through a 6-h virus adsorption period,
resulted in a progressive decrease in the number of foci, with very
few foci present at the highest concentration tested, 20 M. In
contrast, the addition of RO4475417 to the cultures for a 6-h pe-
riod beginning at the end of the virus adsorption period hadmuch
less effect on the focus count. This difference was dramatic at a 10
M concentration of RO4475417 (Fig. 4C).
To confirm that the MKNK inhibitor RO4475417 inhibits a
step in viral entry, we assessed its ability to block entry of pseu-
dotyped HCV particles (HCVpp) (37). These experiments are
complicated by the fact that MKNK contributes to the regulation
of eukaryotic translation through its phosphorylation of eIF4E, a
rate-limiting component of the eukaryotic 7-methylguanosine
cap-binding 4F complex (47). Inhibition of MKNK thus reduces
the efficiency of cap-dependent translation and therefore would
be expected to nonspecifically reduce the expression of luciferase
from pseudotyped lentivirus particles. Nonetheless, we observed
differences in the ability of RO4475417 to suppress luciferase ex-
pression mediated by infection with HCVpp compared to that of
control particles pseudotyped with the vesicular stomatitis virus
envelope (VSVpp) when cells were treated with 2.5 to 5.0 M
from 1 h before to 6 h after inoculation (Fig. 5A). In replicate
independent experiments, the mean 50% infectious concentra-
tion (IC50) of RO4475417 for inhibition ofHCVpp entrywas 3.35
0.05 M, and that for VSVpp entry was 6.95 1.05 M (mean P
value of 0.01 by the extra-sum-of-squares F test). Higher con-
centrations of the inhibitor led to nearly complete suppression of
luciferase expression induced by both HCVpp and VSVpp, con-
sistent with an effect on cap-dependent translation (Fig. 5A). To
control for nonspecific suppression of luciferase translation, we
compared the effects of RO4475417 onHCVpp-mediated lucifer-
ase expression when cells were treated with the compound during
infection (from 1 h before to 6 h after inoculation) versus the 6-h
period immediately following (from 6 to 12 h postinoculation)
(Fig. 5B). Therewas significantly less reduction in luciferase under
the latter conditions, indicating that the effect of RO4475417 is
greatest when it is present during HCVpp entry (Fig. 5B). In con-
trast, the JNK inhibitor RO5108581 demonstrated no dose-re-
lated effect on entry of HCVpp (data not shown).
FIG 5 MKNK inhibition and cellular entry of HCVpp. (A) Impact of increasing concentrations of RO4475417 (MKNK inhibitor) on luciferase expressed by
HCVpp versus VSVpp. Cells were treated with the inhibitor for 1 h prior to and for 6 h during pseudotyped particle infection. Luciferase activity was assayed at
48 h, as shown at the top. Results shown represent mean  SD relative luciferase activity in triplicate cultures and are representative of two independent
experiments. (B) Inhibition ofHCVpp-mediated luciferase expression by RO4475417when added to cell culturemedia 1 h prior to and duringHCVpp infection
(	1 to 6 h, as described for panel A) or following a 6-h incubation with HCVpp (6 to 12 h). Results shown represent mean SE relative luciferase activity. (C)
Inhibition of cap-dependent and HCV IRES-dependent translation following a 6-h exposure to increasing concentrations of RO4475417 (MKNK inhibitor).
Cells were transfected with pRLHL, which expresses a dicistronic transcript containing the HCV IRES within the intercistronic space. Twenty-four h later (time
point 0), cells were treated with RO4475417 for 6 h. Cells were lysed and luciferase activities measured at 48 h. Results shown represent RLuc (cap-dependent
translation initiation) and FLuc (IRES-dependent) activities relative to those in the absence of the compound (100%) and are the means SD from triplicate
cultures. (D) Kinetic analysis of recovery from RO4475417-mediated inhibition of cap-dependent translation. Cells were transfected with pCMV-GLuc, which
expresses secreted GLuc, 24 h prior to drug exposure, as described for panel C. Supernatant fluids were harvested for GLuc assay and replaced with freshmedium
at 6, 24, and 48 h. (E) Lack of an effect of a 6-h exposure to RO4475417 (5M) on cellular abundance of theHCV coreceptors CD81, SR-B1, claudin-1, occludin,
and NPC1L1. Cells were treated with compound for 6 h starting at time point 0 and harvested for immunoblot assays at 6 and 24 h.
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Given the impressive effect of RO4475417 on luciferase ex-
pressed by VSVpp, we further characterized its effects on cellular
translation. For this, we transfected cells with pRLHL (38), a di-
cistronic reporter plasmid in which translation of the upstream
cistron (Renilla luciferase [RLuc]) is initiated in a cap-dependent
fashion, while translation of the downstream cistron (firefly lucif-
erase [FLuc]) is controlled by the HCV IRES placed within the
intercistronic space. Increasing concentrations of RO4475417
strongly inhibited cap-dependent translation (Fig. 5C). Unex-
pectedly, the compound also inhibited HCV IRES-dependent
translation under these conditions, albeit to a lesser extent. To
examine the kinetics of RO4475417-mediated suppression of
translation, we similarly treated cells transfected with pCMV-
GLuc, a reporter plasmid that expresses secreted Gaussia princeps
luciferase (GLuc) in a cap-dependent fashion. Cell culture super-
natant fluids were collected and replaced at the end of a 6-h expo-
sure to increasing concentrations of R04475417 and at 24 and 48 h
after translation. At each interval, secretedGLuc activity was com-
pared to that from untreated cells, allowing a real-time determi-
nation of the rate of recovery from suppression of translation.
These results revealed a dose-dependent length of translation sup-
pression (Fig. 5D), with 75% recovery by 48 h in cells treated with
5 M the compound.
To assesswhether suppression of cap-dependent translation by
R04475417 results in reduced expression of knownHCV corecep-
tors, we determined the abundance of CD81, SR-B1, claudin-1,
occludin, and NPC1L1 proteins in lysates of cells exposed to a 5
M concentration of the compound for 6 h (Fig. 5E). Remark-
ably, this revealed no loss of expression of any of these receptor
molecules either during the period of drug exposure or over the
ensuing 24 h. Thus, despite the strong effects of the compound on
translation, its ability to inhibit HCV entry cannot be attributed to
impaired expression of known cellular receptors.
siRNA-mediated depletion confirms a role for MKNK1 in
HCV entry.There are two genetically distinct isoforms ofMKNK,
MKNK1 and MKNK2 (48). To confirm that entry inhibition by
RO4475417 was indeed related to inhibition of MKNK and to
identify the specific isoform involved, we transfected cells with
siRNAs targeting either or both isoforms. Three days after trans-
fection, the cells were infected with HJ3-5 virus, and infectious
foci were enumerated 2 days later. These knockdowns proved to
be difficult, but
60%knockdown ofMKNK expressionwas con-
firmed by qRT-PCR (MKNK1 and MKNK2) or immunoblotting
(MKNK1 only, due to a lack of antibodies specific for MKNK2)
(Fig. 6A, left and right).MKNK1 knockdown reproducibly caused
a 50% reduction in the number of infectious foci in cells inoc-
ulatedwithHJ3-5 virus, whileMKNK2knockdown caused a slight
but reproducible increase (Fig. 6B). The decreased numbers of
infectious foci followingMKNK1 knockdown could not be attrib-
uted to impaired viral RNA replication, as depletion of neither
MKNK1 norMKNK2 significantly reduced replication of a trans-
fected viral RNA (HJ3-5/GLuc2A) inwhich theGLuc reporter was
inserted between p7 and NS2 of the polyprotein (Fig. 6C).
Sustained suppression of cellular translation following siRNA
knockdown of MKNK (as opposed to short-term chemical inhi-
bition, as shown in Fig. 4C) is likely to interfere with the interpre-
tation of experiments using pseudotyped lentivirus particles, since
their entry is monitored by measuring cap-dependent expression
of a luciferase reporter protein. Indeed, while we observed a 39%
10% (means  standard errors of the means [SEM]) decrease in
luciferase activity expressed byHCVpp followingMKNK1 knock-
down in 3 independent experiments, similar reductions were ob-
served with control VSVpp particles (data not shown). These re-
sults are consistent with general inhibition of translation. In
contrast, knockdown of MKNK2 resulted in a modest increase
(17% 15%) in luciferase expressed by HCVpp.
Despite the confounding effects of MKNK1 inhibition or de-
pletion on cellular translation, the data presented in Fig. 5 and 6
collectively provide strong evidence for a role forMKNK1 inHCV
cell entry. However, we observed no significant change in the ex-
pression level ofMKNK1 at 8 or 24 h after infection at a highMOI
(MOI 5) (Fig. 6D). We did not assess changes in its phosphor-
ylation status of MKNK1 under these conditions due to a lack of
phospho-MKNK1-specific antibodies.
FIG 6 RNAi-mediated knockdown of MKNK1 inhibits HCV cell entry. (A)
(Left) RNAi-mediated decreases in MKNK mRNAs. Total cellular RNA was
extracted from cells following transfection with MKNK1- and MKNK2-spe-
cific siRNAs and assayed for MKNK1 and MKNK2 mRNAs by qRT-PCR.
Means  SD were calculated from replicate experiments. (Right) Immuno-
blots of MKNK1 in lysates from siRNA-transfected cells. MKNK2-specific
antibody was not available. (B) Number of infectious foci in HJ3-5 virus-
inoculated cells following knockdown of MKNK1 andMKNK2. Huh-7.5 cells
were infected by HJ3-5 virus 3 days after siRNA transfection. Two days later,
foci of infected cells were visualized by indirect immunofluorescence and enu-
merated. Results shown represent means SE from two independent exper-
iments. (C) Effect ofMKNK knockdown onHCVRNA replication. Cells were
transfected with HJ3-5/GLuc2A RNA 72 h following transfection with the
indicated siRNAs. GLuc activities secreted by the transfected cells were mea-
sured and plotted as fold change relative to GLuc present 6 h after HCV RNA
transfection (33). Means SE were calculated from two independent experi-
ments. (D) Immunoblot showingMKNK1 expression inHuh-7.5 cells follow-
ing infection with HJ3-5 virus (MOI of 
5). Lysates were prepared at 0 h
(before infection) and 8 and 24 h after infection and were subjected to immu-
noblotting for MKNK1, GAPDH, and HCV core protein.
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DISCUSSION
JNKs are an evolutionarily conserved subgroup of theMAPK fam-
ily that exert a broad influence on a variety of cellular functions,
such as proliferation, apoptosis, differentiation, and develop-
ment. Previous studies suggested that both ERK and p38, other
MAPKs, act to restrict HCV replication. We have demonstrated
that ERK activates mTOR in cooperation with the phosphoinosi-
tide-3 kinase pathway, in turn activating p70 S6 kinase and eIF4E
binding protein and suppressing HCV replication (7). Zhu and
Liu (11) also reported that IL-1 acts to inhibit replication in part
through activation of ERK. Similarly, p38 activationmay contrib-
ute to interferon--mediated anti-HCV activity in association
with activation of MAPK-activated protein kinase 2 (MAP-
KAPK2) (12). Although these observations indicate that MAPKs
are able to negatively regulate HCV replication, the JNKs have not
been investigated previously. We show here, using a cell line har-
boring a subgenomic HCV RNA replicon, that both chemical in-
hibition and RNAi-mediated knockdown of JNK expression en-
hances HCV protein and RNA abundance (Fig. 1 and 2A), while
JNK activation induced by overexpression of JNK2 and MKK73E
suppresses replicon amplification as well as replication of infec-
tious virus in cell culture (Fig. 2B). These data lead us to conclude
that JNK activation suppresses HCV replication, similar to what
has been observed previously with ERK and p38, other members
of the MAPK family.
JNK is known to modulate the replication of certain viruses.
Herpes simplex virus (49), Kaposi’s sarcoma-associated herpesvi-
rus (50), rhesus rotavirus (51), and human immunodeficiency
virus 1 (52) are all suppressed by JNK inhibition, while inhibitors
of JNK enhance replication of influenza virus (53) and varicella-
zoster virus (54). In contrast, coxsackievirus B3 yields are not
altered by JNK inhibition with SP600125 (55). Hence, the effects
of JNK appear to vary with different viruses, possibly reflecting
differences in the host cells and culture conditions as much as in
the virus itself. Ludwig et al. (53) demonstrated that JNK inhibi-
tion suppressed AP-1-dependent IFN- promoter activity, result-
ing in increased yields of influenza virus. We did not detect any
change in basal IFN- promoter activity in RG cells following
siRNA knockdown of JNK (data not shown). This may reflect an
absence of IFN- promoter activation in the replicon cells, be-
cause theHCVNS3/4A protease severely restrains IRF3 activation
by directing the proteolysis of MAVS and TRIF, key adaptor pro-
teins in RIG-I and TLR-3 signaling, respectively (56). Thus, IRF3-
activated genes, including IFN-, are unlikely to play a role in the
suppression of HCV replication by JNK, and the mechanism by
which this occurs remains to be completely elucidated.
In sharp contrast to RNAi-mediated knockdown of JNK (Fig.
2A), the JNK inhibitors AS601245 and SP600125 demonstrated an
inhibitory effect on infection with cell-free HCV (Fig. 2C). There
is little doubt about the specificity of the knockdown, as we ob-
served similar results with 4 different siRNAs targeting distinct
JNK sequences (data not shown). Thus, we attribute this differ-
ence and the inhibition of de novo HCV infection (Fig. 2C) to an
off-target effect of the chemical compounds. This is not surpris-
ing, as Bain et al. (57) reported that SP600125 inhibited 13 of 28
kinases tested with potency at least as great as its activity against
JNK. Although these results were derived from in vitro assays, the
compound is likely to have similar broad effects on kinases in vivo.
The specificity of AS601245 has not been similarly examined, but
it would be no surprise were it to similarly target a variety of
related kinases. Based on the potential for such off-target effects,
we selected 4 kinases as candidates for further study, GAK, CLK2,
TTK, andMKNK, and assessed the ability of chemical compounds
targeting these kinases to interfere with HCV infection. Of these,
RO4475417, an inhibitor targeting MKNK, was uniquely capable
of blocking both an early step in HCV infection (Fig. 4) and
HCVpp entry (Fig. 5). While this compound has strong, negative
effects on both cap-dependent and HCV IRES-dependent trans-
lation (Fig. 5C and D), it did not reduce the abundance of known
HCV receptor molecules under the conditions in which it was
used (Fig. 5E).
As with the JNK inhibitors we tested, it is possible that the
effects we observed with RO4475417 treatment could in part re-
flect off-target inhibition of a kinase other thanMKNK. Although
the compound has demonstrated a high degree of specificity
against an expanded panel of kinases, it is designed to compete
with ATP in the binding site and thus could block the activity of
another kinase. However, unlike the results we obtained with
RNAi-mediated knockdown of JNK, MKNK1 knockdown pro-
vided strong support for a specific role forMKNK1 inHCV entry,
as it significantly reduced the number of cells successfully infected
by HCV in a fluorescent focus formation assay (Fig. 6B) while
having no effect on replication of transfected viral RNA (Fig. 6C).
These results could not be confirmed using pseudotyped lentivi-
rus particles due to suppression of cellular translation following
MKNK1 knockdown. Taken collectively, however, the results we
obtained with authentic infectious HCV following chemical (Fig.
4) or genetic (Fig. 6) knockdown of MKNK1 strongly support a
specific role for this kinase in HCV entry, or possibly another very
early step in replication of infectious virus, such as uncoating of
the viral genome.
The MKNKs were first discovered as ERK substrates (58, 59)
and comprise four proteins, with two isotypes produced from
each of two genes (MKNK1 andMKNK2) (48, 60). These differ in
their cellular localization and degree of regulation by ERK, with
MKNK1a being predominantly cytoplasmic and highly regulated
by ERK and p38MAP kinases.MKNK1b differs fromMKNK1a in
lacking a C-terminal MAPK-binding domain and nuclear export
signal, and it is at least partly nuclear in its distribution and min-
imally regulated by ERK/p38 kinases (48, 60).MKNK1 is involved
in stress responses, cytokine expression, and control of transla-
tion. It positively regulates cap-dependent cellular translation via
phosphorylation of the cap-binding protein, eIF4E, a rate-limit-
ing component of the cap-binding complex eIF4F, and its promo-
tion of translation is important for replication of herpesviruses in
quiescent cells (61, 62) and reactivation of herpesviruses from
latency (63). MKNK1-mediated phosphorylation of eIF4E also
stimulates picornaviral cap-independent translation, and its in-
duction by oncogenic Ras has been associated with the growth of
oncolytic polioviruses in glioblastoma cells (64).WhileMKNK1 is
expressed in liver tissue, it has not been recognized previously to
be a host factor in the HCV life cycle.
Substantial prior evidence supports an important role for ki-
nases in HCV entry. Lupberger et al. (30) recently reported the
results of a genome-wide siRNA screen of kinases involved in
HCV entry. Their primary screen identified a total of 106 kinases
potentially involved in HCVpp entry. Included among these was
MKNK2 but, interestingly, not MKNK1. Further screening with
infectious virus and individual siRNAs reduced this list to 58 ki-
Kim et al.
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nases involved in HCV entry, and apparently it excluded any role
for MKNK2 (30). These authors subsequently focused on kinases
for which specific inhibitors have been approved for clinical use
and demonstrated that the epidermal growth factor receptor
(EGFR) and ephrin receptor A2 (EphA2), both receptor tyrosine
kinases, act as host factors in HCV entry. EGFR activation ap-
peared to enhance a late step in HCV entry by facilitating interac-
tions between the virus coreceptors CD81 and CLDN1. Exactly
how this happens, and what events occur downstream of the re-
ceptor tyrosine kinases, is not clear. Brazzoli et al. (31) demon-
strated that CD81 engagement activates several RhoGTPases, and
that this mediates actin-dependent relocalization of CD81-E2
complexes toward the tight junction. This was shown to occur in
association with Raf/MEK(MAP2K)/ERK signaling, which could
lead toMKNK1 activation. U0126, a chemical inhibitor ofMEK-1
and MEK-2, inhibited HCV infection, and MEK signaling ap-
peared to be required for a very late entry or early postentry step in
replication (31).
Based on these prior studies, it is possible that MKNK1 is acti-
vated by ERKdownstreamof RasGTPase signaling induced by the
receptor tyrosine kinases during HCV entry. While MKNK1 is
likely to be part of a complex network of kinases that are activated
during viral entry (30), the sizable impact of chemical and genetic
inhibition of MKNK1 activity on HCV infection suggests that it
plays a significant role in this process, at least in the Huh-7 hepa-
toma cells we studied. At the same time, it is clear that each of the
3 MAPKs, ERK, p38, and JNK (as shown here), exert strong neg-
ative effects on HCV RNA replication. These contrasting effects
on viral entry and viral RNA replication are surprising and suggest
that there must be exquisite dynamic regulation of their activities
both temporally and spatially during the infection process.
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